<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) is a complex <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic disorders</z:e> including <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> and impaired insulin action and/or insulin secretion </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001513'>Obesity</z:hpo> T2DM has become a serious problem in Japan as in Western countries, with <z:mp ids='MP_0001433'>over-eating</z:mp> and physical inactivity </plain></SENT>
<SENT sid="2" pm="."><plain><z:mp ids='MP_0001261'>Obese</z:mp> Asians have mild degree of <z:e sem="disease" ids="C0028754" disease_type="Disease or Syndrome" abbrv="">adiposity</z:e>, compared with Western subjects </plain></SENT>
<SENT sid="3" pm="."><plain>Unlike total body fat, body fat distribution, especially excess accumulation of visceral fat, correlates with various diabetogenic, atherogenic, prothrombotic and proinflammatory <z:mp ids='MP_0005266'>metabolic abnormalities</z:mp>, which increase the risk of <z:e sem="disease" ids="C0003972" disease_type="Disease or Syndrome" abbrv="ascvd">atherosclerotic cardiovascular disease</z:e> (ACVD) </plain></SENT>
<SENT sid="4" pm="."><plain><z:mp ids='MP_0001261'>Obese</z:mp> patients with T2DM have poor glycemic control with disordered eating behaviors, and complications of <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, leading to ACVD </plain></SENT>
<SENT sid="5" pm="."><plain>The major therapies in <z:mp ids='MP_0001261'>obese</z:mp> T2DM, <z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo> and low insulin sensitivity, available for <z:hpo ids='HP_0001824'>weight loss</z:hpo>, especially visceral fat reduction, include caloric restriction, physical activity and behavior modification </plain></SENT>
<SENT sid="6" pm="."><plain>On the other hand, the major therapies in non-<z:mp ids='MP_0001261'>obese</z:mp> T2DM with insufficient insulin secretion, are insulin-secretory agents and injectable insulin </plain></SENT>
<SENT sid="7" pm="."><plain>For clinically meaningful prevention/reduction in the rate of future ACVD in T2DM, it may be important to stratify T2DM subjects into those with and without visceral <z:hpo ids='HP_0001513'>obesity</z:hpo> and design specific management protocols for each group </plain></SENT>
</text></document>